Excellent
Fully Aligned
Patient Risk:
Low
Summary
The claim that LIPITOR is indicated to reduce the risk of hospitalization for CHF in patients with clinically evident CHD is directly supported by the provided FDA label indications text.
Category Scores
Accurate Statements
LIPITOR is indicated to reduce the risk of hospitalization for congestive heart failure (CHF) in patients with clinically evident coronary heart disease (CHD).
Label Indications (Section 1.1): In patients with clinically evident coronary heart disease, LIPITOR is indicated to "Reduce the risk of hospitalization for CHF."
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claim is an on-label indication statement and does not add dosing, monitoring, or safety instructions beyond what is supported.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement